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The Israeli health system has made considerable progress in reducing deaths amenable to medical care but has
more to do. This commentary describes how progress in this area results from innovation, coverage, quality, and
adherence to treatment. It describes what is being done in Israel and beyond to address each of these factors but
concentrates on the often poorly recognised problem of adherence to treatment, describing the growing evidence
that it is often sub-optimal and reviewing evidence on what can be done to improve it.Introduction
In the accompanying paper, Goldberger and Haklai de-
scribe how the Israeli health system has made consider-
able progress in reducing deaths amenable to medical
care in the past decade [1]. Deaths from these causes
have fallen by slightly over 3% per annum, which is bet-
ter than has been achieved in a number of European
countries, but still not as good as the best performers.
This raises the question of what else needs to be done to
achieve even better results in the next decade.
Reductions in deaths amenable to medical care come
about for four main reasons. The first is innovation, with
new models of care being developed and implemented.
Historically, examples include the discovery of penicillin
as a means to treat common bacterial infections, the de-
velopment of anti-retrovirals to treat HIV infection, and
the use of chemotherapy to treat cancers such as child-
hood leukaemia and testicular cancer. More often, the
effects are less dramatic, as new drugs incrementally im-
prove outcome, such as the use of combination therapy
to treat hypertension. However, innovation alone makes
relatively little contribution to health outcomes; what
matters is that the new approaches to health care reach
those in need. This takes us to the second factor, cover-
age of the population by health care. The impact is most
easily seen where health care is not provided universally,
most notably in the United States, where rates of amen-
able mortality lag increasingly far behind those seen in* Correspondence: martin.mckee@lshtm.ac.uk
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distribution, and reproduction in any mediumEuropean health systems [2]. However, even in Israel,
where coverage is universal, the high level of co-
payments and other costs of obtaining care mean that a
substantially higher proportion of the population forego
treatment than in comparable European countries.[3]
The third factor is quality of care. Improvements in the
outcomes from major trauma in British emergency
departments were not due to innovative treatments or
to improved access to care, given the existence of the
National Health Service. What was found to be import-
ant was a combination of many small changes, such as
improved training of staff in advanced life support,
greater involvement of senior doctors, and the imple-
mentation of quality assurance systems [4]. However,
there is a fourth, which tends to be rather less well
recognised but is likely to be at least as important. This
is adherence to treatment, something which is often
much less than health professionals and policymakers
realise.
What are the priorities?
Which of these should Israeli policy makers prioritise to
improve Israel's relative position with regard to overall
amenable mortality and the pattern of cause-specific
amenable mortality Therapeutic innovation has long ago
moved into the global arena and while there may be eco-
nomic arguments for strengthening the Israeli pharma-
ceutical industry, it is not especially important for
population health. Population coverage should not be a
problem, given the provision of universal coverage, al-
though as Goldberger and Haklai note, coverage is un-
even, both geographically and by ethnicity. There isntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
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cially in a health system that is under increasing finan-
cial constraints that place pressures on staff [5], but
Israel has established functioning quality assurance sys-
tems that attract widespread professional support[6,7]
and achieves good performance on process measures [7].
There has, however, been rather less attention to adher-
ence to prescribed therapy, even though the limited
research that has been done shows high levels of non-
adherence [8]. Thus, while all of these aspects of care
require attention, and in particular the evidence of fore-
gone coverage due to costs of care due to co-payments,
this commentary focuses on only one element, adher-
ence to treatment, while noting that efforts to address
this issue should be part of a comprehensive approach
to achieving health gain.
The evidence from Israel is consistent with follow up
data on patients elsewhere with common chronic condi-
tions showing that up to 70% discontinue their prescribed
treatment [9,10] even though health professionals are
often unaware of it,[11] with one study finding that over
80% of patients would not tell their physicians that they
were not taking their prescribed medicines [12]. Non-
adherence is found among people of all sorts, with little
impact of demographic variables, although some variation
by condition being treated (e.g. higher adherence with
HIV and cancer and lower with diabetes and pulmonary
disease) [13].
Non-adherence matters. Blood pressure control is, un-
surprisingly, substantially associated with adherence to
medication [14]. One study, using data from a clinical
trial, and thus including patients who one might expect to
be more motivated than average, found that a third had
discontinued at least some of the treatment prescribed
(aspirin, beta-blockers, and statins) within 12 months fol-
lowing a myocardial infarction [15]. Those that discontin-
ued treatment were almost four times as likely to die.
Similar findings were reported from a French study [16].
A study in an American managed care organisation found
that over 20% of those with diabetes took their medication
(oral hypoglycemics, antihypertensives, and statins) on at
least 80% of days. Those who did not take their medica-
tion regularly were significantly more likely to be hospita-
lised or die [17]. A similar study of women prescribed
adjuvant hormonal treatment for breast cancer found that
31% discontinued therapy and, of the remainder, 28% did
not adhere regularly to it. Those who discontinued ther-
apy were 26% more likely to die (95% confidence intervals
9-46%) while those not adhering were 49% more likely
(95% confidence intervals 23-81%) [18]. It also matters for
the economy. An analysis using American data finds that
while improved adherence would increase drug costs it
would achieve substantial reductions in overall costs due
to fewer complications and hospitalisations [19].What can be done?
As this brief review shows, considerable further gains
seem possible if people would adhere to medication that
they have been prescribed. But how might this be
achieved? There is no simple answer. A Cochrane Review
found that almost all interventions that were effective in
the long-term care were complex [20]. They included
combinations of more convenient care, information,
reminders, self-monitoring, reinforcement, counselling,
family therapy, psychological therapy, crisis intervention,
manual telephone follow-up, and supportive care. How-
ever, even the most effective interventions did not lead to
large improvements in adherence and treatment outcomes
and the authors stressed the need for more research. Re-
search that has been undertaken in Israel shows that
provision of relevant information on medication [21] and
empowerment of nurses can help [22] although, clearly,
much more research is needed.
On the other hand, there are some obvious issues that
could be addressed. One is cost. There is evidence that
chronically ill patients in the United States are reducing
their purchases of prescription drugs in the current fi-
nancial crisis [23]. Concerns have been expressed that
the complex system of co-payments for pharmaceuticals
in Israel [24] may act as a barrier to adherence [25].
There is also a need to understand better how patients
view their medication. Marshall and colleagues reviewed
systematically 53 qualitative studies of lay perspectives
on hypertension and adherence to treatment, from 16
countries, including Israel [26]. They found a widespread
belief hypertension was due mainly to stress and was
manifested by symptoms such as headache, dizziness or
sweating. Many people believed that, when such symp-
toms abated, their hypertension was resolved and they
discontinue treatment without consulting their position.
Many experienced side-effects that they find unpleasant
and some feared addiction to treatment. In addition to
factors related to their understanding of hypertension
and the importance of treatment, there were also a num-
ber of external factors, such as the time and cost
involved in consulting the physician or obtaining medi-
cation, as well as simple forgetfulness. Research among
older Israelis specifically identified the problems that
arise from multiple medications and where there is lack
of trust in the primary caregiver [27]. Finally, there is
growing evidence that many of the trials that have evalu-
ated new medications may systematically underestimate
the side effects, especially when used in patients with
multiple conditions and therapy [28], and who may be
quite different from those included in trials.[29]Hence,
some of those who do not adhere to prescribed medica-
tion may be making rational choices based on their
weighing up of the perceived benefits and the often all
too apparent side effects.
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In conclusion, the Israeli health system has done well but
there is more to be done, in particular by ensuring equit-
able access to health care, removing financial barriers, and
understanding why patients do not take the medication
they are prescribed and what can be done to help them do
so where it can be established that it will truly benefit
them. There is a clear need for more research, beginning
with empirical studies of the relative roles of the four fac-
tors identified as contributing to cross-national differences
in amenable mortality rates and changes over time. This
should lead to a fuller analysis of the reasons for Israel's
relative position in amenable mortality vis a vis other
countries, as well as the reasons for the cross-regional dif-
ferences within Israel. Turning specifically to adherence to
treatment, there is scope for cross-national comparisons
of adherence rates and empirical analyses of the causes of
differences between countries so that lessons can be
learned from those countries with the best adherence
rates, including how they have used different policy and
programmatic interventions. It is essential that future pol-
icies are fully informed by this emerging evidence.
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